This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-13 and is reviewed periodically as new material appears.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
The first fully terrestrial vertebrates were amniotes. Like their amphibious early tetrapod predecessors, they had lungs and limbs. Amniotic eggs, however, have internal membranes that allow the developing embryo to breathe but keep water in. Hence, amniotes can lay eggs on dry land, while amphibians generally need to lay their eggs in water. The first amniotes apparently arose in the Pennsylvanian subperiod of the Carboniferous. They descended from earlier reptiliomorph amphibious tetrapods, which lived on land that was already inhabited by insects and other invertebrates as well as ferns, mosses and other plants. Within a few million years, two important amniote lineages became distinct: the synapsids, which would later include the common ancestor of the mammals; and the sauropsids, which now include turtles, lizards, snakes, crocodilians and dinosaurs (including birds). Synapsids have a single hole (temporal fenestra) low on each side of the skull. Primitive synapsids included the largest and fiercest animals of the early Permian such as Dimetrodon. Nonmammalian synapsids were traditionally—and incorrectly—called "mammal-like reptiles" or pelycosaurs; we now know they were neither reptiles nor part of reptile lineage. Therapsids, a group of synapsids, evolved in the Middle Permian, about 265 million years ago, and became the dominant land vertebrates. They differ from basal eupelycosaurs in several features of the skull and jaws, including: larger skulls and incisors which are equal in size in therapsids, but not for eupelycosaurs.
Approval by the US Food and Drug Administration followed in December 1993, also for use as an adjuvant (effective when added to other antiseizure drugs) medication to control partial seizures in adults; that indication was extended to children in 2000. Subsequently, gabapentin was approved in the United States for the treatment of pain from postherpetic neuralgia in 2002. A generic version of gabapentin first became available in the United States in 2004. An extended-release formulation of gabapentin for once-daily administration, under the brand name Gralise, was approved in the United States for the treatment of postherpetic neuralgia in January 2011. Gabapentin has been prescribed for a variety of disorders and is one of the more common medications used, particularly in elderly people.
Succimer is indicated for the treatment of lead poisoning in children with blood level measured above 45 μg/dL. The use of dimercaptosuccinic acid is not approved for prevention of lead poisoning in anticipation of exposure in known lead-contaminated environments. Dimercaptosuccinic acid can cross the blood–brain barrier of mice, but it is not known if this is also the case in humans. Even if dimercaptosuccinic acid cannot reverse the damages done to the central nervous system, it might prevent further deterioration. Succimer facilitates urinary excretion of lead, and with sufficiently aggressive treatment, can reduce lead content in the brain. It also increases urinary excretion of copper and zinc. Dimercaptosuccinic acid improved cognitive function in rats that had been exposed to lead, but reduced cognitive function in rats that had not been exposed to lead.
Sources: en.wikipedia.org
Textile stabilization is a conservation method for fiber and yarn-based cloth intended to mitigate damage, prevent degradation and preserve structural integrity. Stabilization is part of a broad set of techniques in the field of conservation and restoration of textiles typically undertaken by a specialist or textile conservator. Appropriate treatment is determined through risk assessment and close examination of a textile's characteristics and the nature of the damage. Organic and synthetic fibers become weak due to age, handling, and environmental exposure and display physical deterioration such as fraying, planar distortion, loss, and change in surface character. Treatment involves reinforcing tensile strength and reintegration of parts for aesthetic, functional, and historic preservation. Methods can include stitching, darning, reweaving, and the attachment of supports through overlays and underlays. Hand-sewing follows the mantra of “gently does it” using fine needles, supple yarns, and a light touch. Heavily damaged and fragile fabrics often require stabilization through adhesive consolidation, though this is less common. It is essential that conservators consider physical and chemical compatibility along with future treatability in choosing a stabilization technique.
12 November The Metropolitan Police condemns "extreme violence from right-wing protesters" during the previous day's demonstrations in London. Seven people are charged with disorder-related offences. The Met Office issues a yellow weather warning for wind and rain ahead of the arrival of Storm Debi which will affect parts of northern England and Wales. 13 November Cabinet reshuffle: Suella Braverman is sacked as home secretary and replaced by James Cleverly. In a surprise move, the former PM David Cameron is appointed as foreign secretary. Thérèse Coffey resigns as environment secretary and is succeeded by Steve Barclay. Richard Holden is made the Conservative party chair, replacing Greg Hands; Victoria Atkins is promoted to health secretary; Laura Trott becomes chief secretary to the Treasury. Following a trial at the Old Bailey, Aine Davis, who spent two years with Islamic State, is sentenced to eight years in prison for possessing a weapon for terrorism purposes and attempting to fundraise for terrorism purposes. Shawn Seesahai, a 19-year-old from Anguilla, is stabbed to death in Wolverhampton. Two boys, aged 12 at the time, are convicted the following year as the UK's youngest knife crime murderers and the youngest overall since the murder of James Bulger. 14 November Two more people come forward with allegations against Russell Brand during his time at the BBC. Seven members of a paedophile gang are found guilty of running a child sex abuse ring in Glasgow, described by the NSPCC as one of the worst cases of its kind in decades.
1292–1319: Dame Péronelle, French herbalist. 13th century Shen Yu Hsiu, Chinese chemist. fl. 1300 Gilette de Narbonne, French physician. Giovanni Boccaccio wrote of her in ‘’The Decameron’’, calling her ‘Donna Medica’; Alfred Duru and Henri Chivot wrote a comic opera about her called Gillette de Narbonne. f. 1307 Trotta da Toya, Napolitan physician. fl. 1308 Francisca di Vestis, Napolian physician. fl. 1309 Maria Gallicia, licensed surgeon. fl. 1313–1325: Ameline la Miresse, French physician. fl. 1318–1324: Adelmota of Carrara was a physician in Padua, Italy. fl. 1318: Alessandra Giliani, Italian anatomist. 1320: Raymunda da Taberna, licensed Napolitan surgeon. fl. 1322: Fava of Manosque, French-Jewish physician. fl. 1322: Jacobina Félicie, Italian physician. fl. 1326: Sara de Sancto Aegidio, French physician. fl. 1326: Sarah de St Giles, French-Jewish physician and medical teacher. fl. 1333: Constanza, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Francisca da Romana, Napolitan physician. fl. 1333: Isabella da Ocre, Napolitan surgeon. fl. 1333: Lauretta Ponte da Saracena Calabria, Napolitan physician. fl. 1333: Margarita da Venosa, licensed Napolitan surgeon, who studied at the University of Salerno She was considered a noteworthy practitioner and counted Ladislaus, king of Naples, as a patient. fl. 1333: Maria Incarnata, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Sibyl of Benevento, Napolitan physician specializing in the plague buboes fl.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.